CF
MCRB icon

Cantor Fitzgerald’s Seres Therapeutics MCRB Stock Holding History

Cantor Fitzgerald’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,874
Closed -$26.2K – 500
2025
Q1 		$26.2K Sell
1,874
-2,913
-61% -$45.6K ﹤0.01% 269
2024
Q4 		$79.6K Sell
4,787
-9,241
-66% -$150K ﹤0.01% 215
2024
Q3 		$265K Buy
+14,028
New +$285K 0.01% 129
2023
Q3 		– Sell
-4,870
Closed -$467K – 602
2023
Q2 		$467K Buy
+4,870
New +$530K 0.01% 380

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Cantor Fitzgerald's MCRB Position: Q2 2025 in Review

Cantor Fitzgerald sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 1,874 shares — an estimated $26.2K sold.

Cantor Fitzgerald first reported a position in MCRB in Q2 2023 and held it in 4 quarters. The position peaked at $467K in Q2 2023. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Cantor Fitzgerald reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 1,874 Seres Therapeutics shares in Q2 2025, an estimated $26.2K.
  • Cantor Fitzgerald first reported a position in Seres Therapeutics in Q2 2023 and held it in 4 quarters.
  • Cantor Fitzgerald's Seres Therapeutics position peaked at $467K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.